These findings indicate a shift in the broader heart failure management landscape, where treatment strategies are becoming more personalized, incorporating newer agents alongside beta-blockers and ACE inhibitors, offering a more nuanced approach to optimizing care in CHF patients. The gene discussed is ACE; the disease is heart failure.